Non-invasive Tools for PSVD Diagnosis
Recruiting · NCT06500403 · Observational (researchers observe without assigning treatment) · Lead sponsor: Nanfang Hospital, Southern Medical University
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Patients treated with platinum-based chemotherapy drugs have the probability of developing PSVD. The diagnosis of PSVD depends on liver biopsy. In addition, the level of portal vein pressure has guiding value in the diagnosis and prognosis of PSVD. Many studies have shown that liver and spleen stiffness have high accuracy in diagnosis and prognosis. The purpose of this study is to evaluate the efficacy of the combination of liver and spleen stiffness in the diagnosis of PSVD and to search for effective biomarkers for the diagnosis of PSVD through a single-center, prospective, observational study.
Who can take part
Inclusion criteria
- Received platinum chemotherapy for organ tumors;
- Ages 18-80;
- sign the informed consent voluntarily.
Exclusion criteria
- Liver pathology suggested cirrhosis;
- Underwent liver transplantation;
- Combined with hepatocellular carcinoma exceeding Milan criteria;
- Complicated with severe heart, kidney, or lung failure;
- Pregnant or lactating women;
- Data is seriously missing;
- Patients were judged not suitable for participation in this study by the researchers.
Where it is running
1 location listed.
- Nanfang hospital, Southern Medical Uiversity - Guangzhou, Guangdong, China